Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on December 11, 2019, 10:53:34 am
-
Selonsertib, an investigational treatment for non-alcoholic steatohepatitis (NASH), worked no better than a placebo for improving liver fibrosis or reducing the risk of cirrhosis, according to a report at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place this week in Boston.
NASH, and its less severe form, non-alcoholic fatty liver disease (NAFLD), are responsible for a growing proportion of advanced liver disease. The build-up of fat in the liver triggers inflammation, which over time can lead to fibrosis (buildup of scar tissue), cirrhosis (severe scarring) and liver cancer. With no effective approved medical therapies, management of the condition involves lifestyle changes such as weight loss and exercise.
For more...
https://www.hepmag.com/article/selonsertib-fails-improve-nashrelated-fibrosis